TY  - JOUR
T1  - REPURPOSING DRUGS FOR CANCER THERAPY
TT  - REPURPOSING DRUGS FOR CANCER THERAPY
AU  - Arzuk, Ege
AU  - Ergüç, Ali
AU  - Karakuş, Fuat
PY  - 2022
DA  - August
DO  - 10.26650/JARHS2021-1133474
JF  - Journal of Advanced Research in Health Sciences
JO  - SABİAD
PB  - Istanbul University
WT  - DergiPark
SN  - 2651-4060
SP  - 41
EP  - 41
VL  - 5
IS  - S-1
LA  - en
AB  - Cancer remains a second leading cause of death worldwide. The economic burden of cancer is increasing day by day due to the morbidity, recurrence, and poor prognosis of this disease. Over the last decades, there is an increasing need to discover and development effective and safe therapeutic agents for cancer. Traditionally, the development and approval of new drugs are long term and also costly. Therefore, this has encouraged scientists to repurposing of known drugs for the treatment of cancer. This strategy has been considered as a good way to offer safe, effective and cost-effective new anticancer drugs. Approximately, 300 non-cancer drugs have been shown to exhibit anticancer effect on different cancer cells, thus they are promising anticancer potential and, candidates for development. However, the appropriate and comprehensive research is required in order to define exact mechanism, dosage and toxicity potential of repurposed drugs. A broad range of therapeutic strategies should be used in order to assess the success of repurposed drugs in replacement of conventional cancer therapies or enhancement of chemotherapy.
KW  - cancer
KW  - drug repurposing
KW  - therapy
KW  - off-target
KW  - oncology
N2  - Cancer remains a second leading cause of death worldwide. The economic burden of cancer is increasing day by day due to the morbidity, recurrence, andpoor prognosis of this disease. Over the last decades, there is an increasing need to discover and development effective and safe therapeutic agents forcancer. Traditionally, the development and approval of new drugs are long term and also costly. Therefore, this has encouraged scientists to repurposingof known drugs for the treatment of cancer. This strategy has been considered as a good way to offer safe, effective and cost-effective new anticancerdrugs. Approximately, 300 non-cancer drugs have been shown to exhibit anticancer effect on different cancer cells, thus they are promising anticancerpotential and, candidates for development. However, the appropriate and comprehensive research is required in order to define exact mechanism, dosageand toxicity potential of repurposed drugs. A broad range of therapeutic strategies should be used in order to assess the success of repurposed drugs inreplacement of conventional cancer therapies or enhancement of chemotherapy.
CR  - Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2012;109(15):276-81.
UR  - https://doi.org/10.26650/JARHS2021-1133474
L1  - https://dergipark.org.tr/en/download/article-file/2497716
ER  -